# Matinas BioPharma Holdings, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Matinas BioPharma Holdings, Inc.). ## Overview Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing lipid nanocrystal (LNC) delivery technology and its lead product candidate MAT2203. The company is currently centered on advancing MAT2203 toward late-stage development and seeking a partner or transaction to monetize the asset and fund future work. ## Products & services • MAT2203 lead LNC product candidate • LNC platform delivery technology • Preclinical and clinical development programs • CMC, regulatory and trial-support activities • Licensing, partnership and asset monetization opportunities - **MAT2203** (70%) — Lead lipid nanocrystal product candidate being advanced through clinical development and partnership discussions. - **LNC Platform Technology** (20%) — Proprietary delivery platform intended to improve formulation, delivery and commercialization potential of drug assets. - **R&D Services and Development Support** (10%) — Internal and outsourced research, clinical, CMC and regulatory work supporting pipeline advancement. - MAT2203 lead LNC product candidate - LNC platform delivery technology - Preclinical and clinical development programs - CMC, regulatory and trial-support activities - Licensing, partnership and asset monetization opportunities ## Customers Matinas does not sell commercial pharmaceutical products today; its economic counterparties are primarily potential licensing partners, biotech/pharma collaborators, CROs and research vendors. The company’s near-term goal is to secure a well-funded third-party partner to advance MAT2203 into Phase 3 and potentially commercialize it after approval. - **Pharmaceutical partnership candidates** (primary) — Large or well-funded biotech/pharma companies that could license MAT2203 and fund Phase 3 development and commercialization. - **Strategic licensing counterparties** (primary) — Companies evaluating the LNC platform or related assets for non-dilutive licensing or acquisition. - **Clinical research vendors** (secondary) — CROs, laboratories and consultants that provide trial design, execution, analysis and regulatory support. - **Government and third-party funding sources** (secondary) — NIH and other non-dilutive funding providers that may support preclinical or clinical work. - Biotech/pharma partners seeking rights to MAT2203 - Potential licensees interested in the LNC platform - CROs and clinical vendors supporting trials - Consultants and regulatory specialists for development work - Future commercial partners if MAT2203 reaches approval ## Geography The company is headquartered in the United States and its disclosed operating footprint is centered on U.S.-based R&D, regulatory and financing activities. No country-level revenue disclosure is provided because Matinas is still pre-commercial and has not reported meaningful product sales. - Headquartered in the United States - R&D and regulatory work are primarily U.S.-based - Clinical studies may involve U.S. CROs and NIH support - No meaningful commercial geography yet disclosed - Future partner commercialization could expand global reach ## Strategy Matinas is prioritizing a partnership or licensing transaction for MAT2203 to secure non-dilutive capital and accelerate late-stage development. At the same time, it is conserving cash, evaluating additional strategic options and preserving flexibility to in-license assets or pursue a merger if that creates more value. - **Partner MAT2203** (short-term) — A funded partner can advance the asset faster and reduce Matinas' capital burden. - **Preserve liquidity** (short-term) — The company is loss-making and needs to extend runway while it seeks strategic options. - **Broaden strategic optionality** (medium-term) — Additional assets or a merger could create value if MAT2203 monetization is delayed. - Secure a partner to fund MAT2203 Phase 3 development - Monetize MAT2203 through licensing or sale - Conserve cash while reducing operating burn - Evaluate in-licensing or merger alternatives - Use non-dilutive funding to avoid excessive dilution ## Risks Matinas is a pre-revenue biotech with a high dependence on external financing and successful partnering of MAT2203. Its business model concentrates risk in a single lead asset, while clinical, regulatory, dilution and warrant-related valuation risks can all materially affect results and liquidity. - **Financing shortfall / going concern pressure** [critical] — The company expects continued losses and needs new capital to fund operations and trials. - **MAT2203 development failure or delay** [high] — Value creation depends heavily on advancing the lead candidate into Phase 3 and beyond. - **Partnering and licensing execution risk** [high] — The strategy relies on finding a capable third-party partner on acceptable terms. - **Dilution from equity financings** [high] — Management may need to issue common stock or convertible securities to raise funds. - **Warrant and preferred stock complexity** [medium] — Recent financings included warrants and preferred stock that can affect reported earnings and dilution. - Dependence on external capital to fund operations - Single-asset concentration in MAT2203 - Clinical and regulatory failure risk in late-stage development - Dilution risk from equity or convertible financings - Warrant liability revaluation can create earnings volatility ## Accounting The most important accounting issues are R&D expense classification, fair value measurement of warrants and the assessment of goodwill and intangible assets. Because the company is pre-commercial and financing through complex securities, non-cash valuation changes and impairment judgments can materially affect reported earnings and balance sheet values. - **Warrant liability fair value** — Can materially move other income/expense and net loss - **Research and development expense timing** — Affects operating loss and quarter-to-quarter comparability - **Goodwill and intangible impairment** — Potential non-cash write-downs - **Stock-based compensation** — Raises operating expenses without cash outflow - R&D spending is the main operating cost and tracks trial progress - Warrants may be equity- or liability-classified depending on terms - Warrant liabilities are remeasured each period at fair value - Goodwill and intangible assets require impairment testing - Recent financing costs and stock-based compensation affect reported loss --- *Last updated: 2026-04-28T20:26:33.638239+00:00*